Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Total Debt (2022 - 2025)

Historic Total Debt for Century Therapeutics (IPSC) over the last 3 years, with Q3 2025 value amounting to $8.3 million.

  • Century Therapeutics' Total Debt changed N/A to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year change of. This contributed to the annual value of $10.2 million for FY2022, which is N/A changed from last year.
  • As of Q3 2025, Century Therapeutics' Total Debt stood at $8.3 million.
  • Century Therapeutics' Total Debt's 5-year high stood at $10.3 million during Q1 2023, with a 5-year trough of $8.3 million in Q3 2025.
  • For the 3-year period, Century Therapeutics' Total Debt averaged around $9.9 million, with its median value being $10.1 million (2022).
  • Data for Century Therapeutics' Total Debt shows a peak YoY increase of 278.5% (in 2023) and a maximum YoY decrease of 278.5% (in 2023) over the last 5 years.
  • Quarter analysis of 3 years shows Century Therapeutics' Total Debt stood at $10.2 million in 2022, then increased by 0.55% to $10.3 million in 2023, then decreased by 19.02% to $8.3 million in 2025.
  • Its Total Debt stands at $8.3 million for Q3 2025, versus $10.3 million for Q1 2023 and $10.2 million for Q4 2022.